CD276 and prostate cancer: We also profiled XmAb808 binding to cancer cell lines for use in immune response assays, including A431 epidermoid cancer cells, 22Rv1 prostate cancer cells, and LOX-IMVI melanoma cells, expressing 196,000, 86,000, and no B7-H3 antigens, respectively.